SLU-PP-332 and Retatrutide Together: What Is Known
SLU-PP-332 and Retatrutide taken together: what each one is, how each is regulated, and what is known about combining them.
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Interaction notes
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Retatrutide is not FDA approved, and we have no sourced data on combining it with SLU-PP-332.
Each component
Side by side
Showing 11 of 13 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.
| Field | SLU-PP-332 | Retatrutide |
|---|---|---|
| Class | ERR agonist (not a peptide) | GLP-1 / GIP / glucagon triple agonist |
| Also called | slupp, SLU-PP | reta, GLP-3, LY3437943 |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Not FDA approved · research chemical | Investigational · phase 3 |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | WADA status unclearSLU-PP-332 is not named. S4.4 lists AMPK activators, PPAR-delta agonists and Rev-erb agonists; SLU-PP-332 is an ERR agonist, which the list does not mention. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. | Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. |
| Half-life | No published half-life foundPubMed search, 2 Oct 2026 | approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040 |
| Evidence strength | Animal evidence, 2 of 4Strongest: The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 | Human RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954 |
| Human studies we summarised | 0 human (0 randomized or controlled) of 7 summarised | 11 human (11 randomized or controlled) of 16 summarised |
| Typical study doses | Not reported in study abstractsPubMed search, 2 Oct 2026 |
|
| Vial sizes sold | 5 mg | 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg |
| US searches per month | 27,100 · −38% searches | 823,000 · +172% searches |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
What people search
- slu pp 332 with retatrutide40/mo
- slu pp 332 and retatrutide together30/mo
- retatrutide and slu pp 33230/mo
- slu pp 332 and retatrutide20/mo
- slu pp 332 retatrutide10/mo
US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.
Sources
- 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 6A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 7PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 10Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 11Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
- 12PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND ("SLU-PP-332"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.